Hansen Medical Names Joseph Guido as Vice President Marketing & Business Development

MOUNTAIN VIEW, CA--(Marketwire - April 02, 2012) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it has named veteran medical device sales and marketing executive Joe Guido Vice President Marketing and Business Development. Mr. Guido will report directly to President and Chief Executive Officer Bruce J Barclay.

Joe has more than 20 years of sales and marketing experience for a variety of medical device companies including Intuitive Surgical, Abbott Vascular Devices and Stryker Endoscopy, generating experience in cardiology, vascular and surgical markets. Throughout his career, Mr. Guido has excelled as a sales and marketing professional, capturing record sales growth through innovative strategies across the medical device industry.

"Joe is a proven leader with an outstanding career commercializing products in a breadth of markets, making him an excellent addition to the team," Barclay said. "Joe's track record of developing and executing successful global marketing strategies, launching new products, capturing market share in both established and emerging markets, and forging long-term partnerships with both hospitals and physicians, will prove invaluable to Hansen Medical. This will be particularly evident as we build on our EP business and pursue opportunities in the vascular market with the launch of our Magellan Robotic System in Europe and with the expected launch of that product in the U.S."

"I am excited to be joining the Hansen Medical team at this important inflection point in the Company's history," said Guido. "Flexible robotics in both vascular and EP applications has the potential to transform how interventional procedures are performed. I believe Hansen is uniquely positioned to take advantage of this opportunity with its compelling value proposition to hospitals, physicians and patients. In addition, the Company has developed a strong foundation for a focused and controlled launch strategy with an enhanced sales team, robust training and physician support in preparation for the expected launch of the Magellan System in the U.S. Further, I am excited to work with the team at this critical time in order to drive a successful go-to-market strategy and realize our position as an industry leader in flexible robotics."

Prior to joining Hansen Medical, Joe spent five years as Vice President of Sales and Marketing at Novare Surgical Systems, Inc., a privately-held medical device company that developed innovative products for minimally invasive surgery. Previous to Novare, he was the Director of Global Strategic Marketing for Abbott Vascular Devices' vessel closure business, and Vice President of Global Marketing at Intuitive Surgical, a public medical device company specializing in surgical robotic systems. While at Intuitive, Mr. Guido led the marketing group while the organization experienced revenue growth of nearly 40% year-over-year. Joe also served 5 years at Stryker Endoscopy, a division of publically-traded Stryker Corporation, where he last operated as Director of Marketing, driving product strategy and business development efforts that generated over $150 million for the division.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Sensei® X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei X System and Artisan Control Catheter are cleared for use during EP procedures, such as guiding catheters in the treatment of AF, and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. The Company's Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone conformity assessment and CE marking and are commercially available in the European Union.
In the U.S., the Magellan™ Robotic System, the NorthStar™ Robotic Catheter and accessories are the subject of a current filing with the FDA and are not commercially available. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, expectations, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the anticipated growth of Hansen's flexible robotic technology in both EP and vascular applications. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory and sales challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the uncertain timelines, costs and results of pre-clinical and clinical trials; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; the effect of credit, financial and economic conditions on capital spending by our potential customers; our ability to manage expenses and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on March 15, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), and Sensei are registered trademarks of Hansen Medical, Inc. in the United States and other countries.